Search
Lusutrombopag
go.drugbank.com/drugs/DB13125ApprovedInvestigationalLusutrombopag was approved by the FDA on July 31st, 2018 for the same therapeutic indication under the market name Mulpleta. … Lusutrombopag is an orally bioavailable thrombopoietin receptor (TPOR) agonist developed by Shionogi & Company (Osaka, Japan).
Glycerol phenylbutyrate
go.drugbank.com/drugs/DB08909ApprovedInvestigationalChemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Lisdexamfetamine
go.drugbank.com/drugs/DB01255ApprovedInvestigational[L48285] Lisdexamfetamine works to treat attention deficit hyperactivity disorder and binge eating disorder [A2230] by blocking dopamine and norepinephrine reuptake and increasing their levels in the extraneuronal … [A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeArgatroban
go.drugbank.com/drugs/DB00278ApprovedInvestigationalArgatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. … Parental anticoagulants must be stopped and a baseline activated partial thromboplastin time must be obtained prior to administering argatroban.
Atidarsagene autotemcel
go.drugbank.com/drugs/DB17538ApprovedInvestigational[L45191] Libmeldy was granted orphan designation by the EMA in April 2007, and was issued a marketing authorization in the EU in December 2020 for the treatment of certain manifestations of metachromatic
Gilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigational[A40044] Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. … [A40036] It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies.
Bretylium
go.drugbank.com/drugs/DB01158ApprovedRecent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site. … The primary mode of action for bretylium is thought to be inhibition of voltage-gated K(+) channels.
Synonyms: 2-bromo-N-ethyl-N,N-dimethylbenzenemethanaminium, N-ethyl-N,N-dimethyl-2-bromobenzenemethanaminiumDisulfiram
go.drugbank.com/drugs/DB00822ApprovedInvestigationalIt is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. … It acts by inhibiting aldehyde dehydrogenase.
Synonyms: N,N,N',N'-tetraethylthiuram disulfide, 1,1'-dithiobis(N,N-diethylthioformamide)Roxithromycin
go.drugbank.com/drugs/DB00778ApprovedInvestigationalWithdrawnRoxithromycin exerts its antibacterial action by binding to the bacterial ribosome and interfering with bacterial protein synthesis. … It was shown to be more effective against certain Gram-negative bacteria, particularly _Legionella pneumophila_.
Synonyms: (9E)-erythromycin 9-(O-((2-methoxyethoxy)methyl)oxime)International brands: Neo-Suxigal, Ao Ge ShenBitolterol
go.drugbank.com/drugs/DB00901ApprovedWithdrawnBitolterol mesylate was used to treat bronchospasms in asthma and COPD. It is a beta-2-adrenergic receptor agonist. Bitolterol was withdrawn from the market by Elan Pharmaceuticals in 2001.
Synonyms: 4-(2-(tert-butylamino)-1-hydroxyethyl)-o-phenylene di-p-toluate, 4-[2-(tert-butylamino)-1-hydroxyethyl]-o-phenylene di-p-toluate